Redding S W, Stiegler K E
Oral Surg Oral Med Oral Pathol. 1983 Aug;56(2):145-8. doi: 10.1016/0030-4220(83)90279-7.
Approximately 15 percent of patients with hemophilia A will develop inhibitors (antibodies) to Factor VIII after replacement infusion. Since Factor VIII replacement therapy is the mainstay of treatment in the hemophiliac, destruction of infused Factor VIII by inhibitors presents significant problems in the treatment of these patients. Different methods of treatment are discussed, including infusion of high doses of Factor VIII and infusion of prothrombin-complex concentrate. Two inhibitor patients who presented for dental treatment are examined. One patient had very low inhibitor titers, and the other had very high inhibitor titers. These patients show that dental treatment must be individualized according to severity of the disease process.
约15%的甲型血友病患者在进行替代输注后会产生针对凝血因子VIII的抑制剂（抗体）。由于凝血因子VIII替代疗法是血友病治疗的主要手段，抑制剂对输注的凝血因子VIII的破坏给这些患者的治疗带来了重大问题。文中讨论了不同的治疗方法，包括大剂量输注凝血因子VIII和输注凝血酶原复合物浓缩剂。对两名前来接受牙科治疗的抑制剂患者进行了检查。一名患者的抑制剂效价非常低，另一名患者的抑制剂效价非常高。这些患者表明，牙科治疗必须根据疾病进程的严重程度进行个体化。
